Matches in SemOpenAlex for { <https://semopenalex.org/work/W2343287988> ?p ?o ?g. }
Showing items 1 to 78 of
78
with 100 items per page.
- W2343287988 endingPage "3559" @default.
- W2343287988 startingPage "3559" @default.
- W2343287988 abstract "3559 Purpose: A recent phase-I-study demonstrated that capecitabine (Xeloda) can safely be combined with pelvic radiotherapy in patients with rectal cancer (Dunst et al, JCO 2002). We conducted a phase-II-study for to confirm safety and efficacy of chemoradiation with Xeoda as preoperative therapy in locally advanced rectal cancers. Patients & methods: 98 patients (median age 65 years, range 34 - 81years) with advanced rectal cancers (cT3–4 or extensive nodal involvement) were recruited from 7 centers in the period from 6/2001 through 11/2003. Therapy consisted of preoperative chemoradiation (50.4Gy in 28 fractions + 5.4Gy boost, Xeloda 825mg/m2 b.i.d. from first to last day of radiotherapy) followed by surgery 6 weeks later. At the time of this analysis (Dec-2003), 58 patients have completed therapy and are evaluable for baseline characteristics and toxicity (N=58) as well as clinical (N=49) and pathological response (N=50). All patients had advanced disease (cT4: 50%, cT3: 48%, cT2: 2%, cN+: 55%). Results: Chemoradiation with Xeloda was well tolerated with no or mild to moderate toxicity in the vast majority of patients. No treatment-related grade 4-toxicity was observed (except a period of hyperglycemia in a patient with diabetes). Main grade 3 toxicities included leuko- and lymphopenia (10%), diarrhea (4%), hypopotassemia (4%) as well as local skin erythema in the radiation fields, bilirubin increase, hypocalcemia and hyponatremia (each in 1 pat.). Clinical response (evaluated 6 weeks after chemoradiation) was observed in 30/49 patients with 28 cPR (57%) and 2 cCR (4%). All patients underwent surgery with 46 R0-resections (92%) and 4 R1-resections (8%). Downstaging of the primary tumor (cT < pT) occurred in 37 pats (74%). A pCR was observed in 2 patients (4%) with 1 additonal case with only pTis in the resection specimen (2%). Conclusions: This phase-II study confirmed that Xeloda is an adequate substitute for continuous infusional 5-FU in preoperative chemoradiation regimens with regard to the favorable toxicity profile and response. Author Disclosure Employment or Leadership Consultant or Advisory Stock Ownership Honoraria Research Funding Expert Testimony Other Remuneration Roche Roche" @default.
- W2343287988 created "2016-06-24" @default.
- W2343287988 creator A5007565502 @default.
- W2343287988 creator A5036887610 @default.
- W2343287988 creator A5040863463 @default.
- W2343287988 creator A5048176919 @default.
- W2343287988 creator A5049767199 @default.
- W2343287988 creator A5073827670 @default.
- W2343287988 creator A5074558569 @default.
- W2343287988 creator A5078003238 @default.
- W2343287988 creator A5081805077 @default.
- W2343287988 date "2004-07-15" @default.
- W2343287988 modified "2023-10-06" @default.
- W2343287988 title "Phase-II-study of preoperative chemoradiation with capecitabine in rectal cancer" @default.
- W2343287988 doi "https://doi.org/10.1200/jco.2004.22.90140.3559" @default.
- W2343287988 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/28016547" @default.
- W2343287988 hasPublicationYear "2004" @default.
- W2343287988 type Work @default.
- W2343287988 sameAs 2343287988 @default.
- W2343287988 citedByCount "13" @default.
- W2343287988 countsByYear W23432879882012 @default.
- W2343287988 countsByYear W23432879882016 @default.
- W2343287988 countsByYear W23432879882021 @default.
- W2343287988 crossrefType "journal-article" @default.
- W2343287988 hasAuthorship W2343287988A5007565502 @default.
- W2343287988 hasAuthorship W2343287988A5036887610 @default.
- W2343287988 hasAuthorship W2343287988A5040863463 @default.
- W2343287988 hasAuthorship W2343287988A5048176919 @default.
- W2343287988 hasAuthorship W2343287988A5049767199 @default.
- W2343287988 hasAuthorship W2343287988A5073827670 @default.
- W2343287988 hasAuthorship W2343287988A5074558569 @default.
- W2343287988 hasAuthorship W2343287988A5078003238 @default.
- W2343287988 hasAuthorship W2343287988A5081805077 @default.
- W2343287988 hasConcept C121608353 @default.
- W2343287988 hasConcept C126322002 @default.
- W2343287988 hasConcept C126894567 @default.
- W2343287988 hasConcept C141071460 @default.
- W2343287988 hasConcept C143998085 @default.
- W2343287988 hasConcept C2777909004 @default.
- W2343287988 hasConcept C29730261 @default.
- W2343287988 hasConcept C31760486 @default.
- W2343287988 hasConcept C509974204 @default.
- W2343287988 hasConcept C526805850 @default.
- W2343287988 hasConcept C71924100 @default.
- W2343287988 hasConcept C90924648 @default.
- W2343287988 hasConceptScore W2343287988C121608353 @default.
- W2343287988 hasConceptScore W2343287988C126322002 @default.
- W2343287988 hasConceptScore W2343287988C126894567 @default.
- W2343287988 hasConceptScore W2343287988C141071460 @default.
- W2343287988 hasConceptScore W2343287988C143998085 @default.
- W2343287988 hasConceptScore W2343287988C2777909004 @default.
- W2343287988 hasConceptScore W2343287988C29730261 @default.
- W2343287988 hasConceptScore W2343287988C31760486 @default.
- W2343287988 hasConceptScore W2343287988C509974204 @default.
- W2343287988 hasConceptScore W2343287988C526805850 @default.
- W2343287988 hasConceptScore W2343287988C71924100 @default.
- W2343287988 hasConceptScore W2343287988C90924648 @default.
- W2343287988 hasIssue "14_suppl" @default.
- W2343287988 hasLocation W23432879881 @default.
- W2343287988 hasOpenAccess W2343287988 @default.
- W2343287988 hasPrimaryLocation W23432879881 @default.
- W2343287988 hasRelatedWork W1971387685 @default.
- W2343287988 hasRelatedWork W2029040122 @default.
- W2343287988 hasRelatedWork W2052195758 @default.
- W2343287988 hasRelatedWork W2145753255 @default.
- W2343287988 hasRelatedWork W2601851885 @default.
- W2343287988 hasRelatedWork W2612131508 @default.
- W2343287988 hasRelatedWork W2999149094 @default.
- W2343287988 hasRelatedWork W349909140 @default.
- W2343287988 hasRelatedWork W4233379803 @default.
- W2343287988 hasRelatedWork W4252691069 @default.
- W2343287988 hasVolume "22" @default.
- W2343287988 isParatext "false" @default.
- W2343287988 isRetracted "false" @default.
- W2343287988 magId "2343287988" @default.
- W2343287988 workType "article" @default.